Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

  • Bioorg Med Chem Lett. 2007 Mar 1;17(5):1250-3. doi: 10.1016/j.bmcl.2006.12.018.
Michael P Clark  1 ,  Kelly M George ,  Roger G Bookland ,  Jack Chen ,  Steven K Laughlin ,  Kumar D Thakur ,  Wenlin Lee ,  Jan R Davis ,  Ed J Cabrera ,  Todd A Brugel ,  John C VanRens ,  Matthew J Laufersweiler ,  Jennifer A Maier ,  Mark P Sabat ,  Adam Golebiowski ,  Vijay Easwaran ,  Mark E Webster ,  Biswanath De ,  George Zhang
Affiliations
  • 1. Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, OH 45040, USA. [email protected]
PMID: 17189692 DOI: 10.1016/j.bmcl.2006.12.018
Abstract

A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.